Ganciclovir (GCV) and its lipophilic elaidic acid ester protype FM3A/0 cells. Strikingly, mono-, di-and tri-phosdrug E-GCV were evaluated for their antiherpetic, cytosphate metabolites of GCV were retained for a substantatic and metabolic properties. E-GCV proved exquisitely tially longer time in E-GCV-treated cells (half-life inhibitory to the replication of herpes simplex virus type 1 approximately 50 h) than in GCV-treated cells (half-life (HSV-1) and HSV-2 in cell cultures (50% effective concenapproximately 20 h). The longer retention time of the tration (EC 50 ): 0.002 M). It was five-to 10-fold more GCV metabolites most likely explains why E-GCV is effective than its parent drug GCV. E-GCV was at least superior to GCV against herpes simplex virus replication 2000-fold more cytostatic to HSV-1 or HSV-2 thymidine and HSVtk gene-transfected tumor cell proliferation. kinase (tk) gene-transfected mammary carcinoma FM3A
Taking into account the marked stability of E-GCV in tk −
/HSVtk
+ tumor cells than to the corresponding nonhuman plasma and its much higher lipophilicity than transfected tumor cells. The cytostatic activity of E-GCV
GCV, E-GCV should be considered as an effective lipoto the HSVtk gene-transfected tumor cells was far philic prodrug of GCV with a markedly enhanced cytosuperior to that of GCV. Metabolic studies revealed that static activity in HSVtk gene-transfected tumor cells both GCV and E-GCV were converted to the mono-, dicompared with parental ganciclovir. Its usefulness in the and tri-phosphate derivatives of GCV to a markedly combined gene/chemotherapy of HSVtk gene-transhigher extent in FM3Atk − /HSV-1 tk + cells than in wildfected tumors should be further pursued.
Keywords: HSV-1 thymidine kinase; gene therapy; ganciclovir elaidic ester A variety of nucleoside analogues including 9-[(2-hydroxyethoxy)methyl]guanine (acyclovir, ACV) and 9-[(1,3-dihydroxy-2-propoxymethyl]guanine (DHPG, ganciclovir, GCV) [1] [2] [3] [4] have been reported to selectively inhibit herpes simplex virus and/or cytomegalovirus infections. The acyclic guanosine derivatives ACV and GCV owe their antiherpetic activity to a selective recognition as a substrate by the HSV-encoded thymidine kinase (tk), but not by its cellular counterpart or other cellular kinases. 3, 5 Consequently, ACV and GCV display little cytotoxicity for noninfected cells. Interestingly, ganciclovir has been shown to be cytostatic against a variety of tumor cell lines transfected with the HSV-1 or HSV-2 tk gene. [6] [7] [8] [9] [10] Several investigators have also reported the pronounced inhibitory effects of GCV on the growth of tumors in mice or rats inoculated with HSV-1tk gene-producing packaging cells. 9, [11] [12] [13] [14] [15] The combined gene/chemotherapy approach has recently entered clinical trials, with ganciclovir as the chemotherapeutic agent. We have now performed anti-viral, cytostatic and metabolic investigations on the elaidic acid ester prodrug derivative of GCV (designated E-GCV) (Norsk Hydro, Porsgrunn, Norway) ( Figure 1 ). This GCV prodrug emerged from a variety of closely related lipophilic GCV derivatives as the drug candidate for further biological experiments.
When ganciclovir (GCV) and its elaidic acid ester derivative E-GCV were evaluated for their antiherpetic activity, GCV inhibited HSV-1 and HSV-2 replication in HEL cell cultures at an EC 50 of 0.01 and 0.028 M, respectively (Table 1 ). E-GCV proved about five-to 10-fold more inhibitory than GCV to HSV-1 and HSV-2. The free fatty acid elaidic acid did not show any antiviral activity by itself at a concentration as high as 100 M. Both GCV and E-GCV were 1000-to Ͼ5000-fold less inhibitory to the replication of a thymidine kinase (tk)-deficient HSV-1 strain, which points to the marked dependence of the activity of GCV and E-GCV on the HSV-encoded thymidine kinase. The reference compound acyclovir (ACV) showed an antiviral activity that was comparable to that of GCV. E-GCV proved 3.5-fold more inhibitory to HEL cell proliferation than GCV, and was also approximately 10-fold more cytotoxic to HEL cells. The fact that elaidic acid showed CC 50 and MCC values that were slightly higher than the cytostatic and cytotoxic values recorded for E-GCV (Table 1 ) led us to assume that the toxicity seen for E-GCV is mainly derived from the fatty acid moiety of the drug.
GCV and E-GCV were also pre-exposed to HEL and Vero cell cultures for 24 h, after which time period the cell cultures were carefully and repeatedly washed to remove residual drug and subsequently infected with HSV-1 at 100 CCID 50 . Whereas GCV and ACV completely lost their inhibitory potential against HSV-1 in Vero cell cultures (EC 50 : Ͼ400 M), E-GCV retained a marked antiviral efficacy (EC 50 : 6 M) ( Figure 2 ). In similar antiviral experiments in which the drugs were pre-exposed for 24 h to HEL cell cultures before careful removal of the drugs and subsequent infection with HSV-1, GCV retained some antiherpetic activity (EC 50 : 29 M), whereas E-GCV was active at a 100-fold lower concentration (EC 50 : 0.38 M). Thus, E-GCV exhibited much higher antiviral activity than GCV when the compounds were exposed to the cells before infection ( Figure 2 ). It was also ascertained that E-GCV had no direct virucidal effect on herpes simplex virus or human cytomegalovirus upon preincubation of free virus particles with the drug (data not shown).
To compare the cytostatic activity of GCV and E-GCV against tumor cells transfected by the thymidine kinase gene of HSV-1 or HSV-2, murine mammary carcinoma FM3A, its thymidine kinase-deficient derivative (FM3Atk − ) and two FM3Atk
− cell lines transfected with either the HSV-1 or HSV-2tk gene were exposed to GCV and E-GCV (Table 2) . Both GCV and E-GCV were virtually devoid of marked cytostatic activity against FM3A/0 and FM3Atk − cells (IC 50 : 206 -Ͼ400 M). Also the free elaidic acid proved virtually nontoxic (IC 50 : у500 M). However, FM3Atk The methods for evaluating the cytostatic effects of the test compounds against HSVtk gene-transfected tumor cells have been described previously. 17, 18 Briefly, 5 × 10 4 cells were suspended in growth medium and added to microplate wells in the presence of varying concentrations of the test compounds. The FM3A cells were allowed to proliferate for 48 h at 37°C in a humidified CO 2 -controlled atmosphere. At the end of the incubation period, the cells were counted in a Coulter counter. The inhibitory concentrations of GCV and E-GCV for the different FM3A cell lines listed in Table 2 are the means for at least five independent experiments. The inhibitory concentrations of elaidic acid and ACV are the means for two to three independent experiments. The standard deviations of the data are within the acceptable range of biological variation for the majority of the cases (ie 5-20%). a 50% Inhibitory concentration, or compound concentration required to inhibit tumor cell proliferation by 50%. /HSV-2tk + ) more inhibitory to the HSVtk gene-transfected cells. Its selectivity index was 50-fold lower than that of GCV and at least Ͼ300 to Ͼ700-fold lower than that of E-GCV.
Figure 2 Retention of the anti-HSV-1 activity of GCV (ᮀ) and E-GCV (a) in HSV-1-infected Vero and Hel cell cultures after pre-exposure of the cell cultures with drug for 24 h and subsequent careful washing of the cell monolayers before HSV-1 infection. Serial dilutions of GCV or E-GCV (diluted in EMEM containing 2% fetal calf serum and 2 mm l-glutamine) were added to either confluent HEL or Vero cell cultures in 96-well microtiter plates. After a 24 h preincubation period at 37°C, the cell cultures were thoroughly washed (four times) with 200 l of EMEM (without serum). The cell cultures were then infected with 100 CCID 50 of HSV-1 (KOS) for 1 h after which the virus inoculum was removed and the cells further incubated in EMEM (containing 2% FCS). The cytopathic effect was evaluated under an inverted microscope at 3 days after infection
To investigate the molecular mechanism of improved cytostatic activity of E-GCV over GCV, [8] [9] [10] [11] [12] [13] [14] C]-labeled GCV and E-GCV were exposed to FM3A/0 and FM3Atk − /HSV-1tk + cell cultures for 2, 6 and 24 h. After the incubation period, the cells were carefully washed and cell extracts were prepared for HPLC analysis. As evident from Table 3a and b, conversion of [8] [9] [10] [11] [12] [13] [14] C]GCV to its 5Ј-mono-, 5Ј-di-and 5Ј-tri-phosphate derivatives was markedly more pronounced in HSV-1tk gene-transfected FM3A cells than wild-type FM3A/0 cells. In fact, triphosphate metabolites of GCV appeared at a 30-to 60-fold higher extent in FM3Atk + cells increased progressively in function of the incubation time. For example, whereas after 2 h of incubation none of the GCV metabolites were measurable yet in FM3A/0 cells, they became detectable at 6 h of incubation and further increased two-to five-fold upon 24 h of incubation. In FM3Atk
+ cells the phosphorylated GCV deriva- 14 C]GCV (5 Ci per bottle). At 2, 6 or 24 h, cells were centrifuged at 200 g, washed twice with cold medium, and precipitated with cold (66%) methanol. After centrifugation at 10 000 g for 3 min, the supernatants were subjected to high performance liquid chromatography analysis using a Partisphere-SAX column (Whatman, NJ, USA). A linear gradient of 5 mm (NH 4 )H 2 PO 4 , pH 5.0 (buffer A) to 500 mm (NH 4 )H 2 PO 4 , pH 5.0 (buffer B) was used to separate the metabolites as follows: 5 min of 100% buffer A, 15 min of a linear gradient to 10% buffer B, 15 min of a linear gradient to 100% buffer B, 10 min of 100% buffer B, 5 min of a linear gradient to 100% buffer A, and 5 min of equilibration with buffer A. The different fractions of the eluates were assayed for radioactivity in a toluene-based scintillant. The elution times of GCV and its 5Ј-monophosphate, 5Ј-diphosphate, and 5Ј-triphosphate derivatives were 2-3, 9-10, 16-17 and 27-28 min, respectively. ND, not detectable. tives were already evident at 2 h, and increased to approximately five-to 10-fold upon 6 h and to 15- C]GCV preparation were found to be responsible for the transient appearance of GMP, GDP and GTP in the cell extracts (data not shown).
When [8] [9] [10] [11] [12] [13] [14] C]E-GCV was exposed to wild-type and HSV-1tk gene-transfected FM3A cell cultures, no marked differences in GCV metabolite levels were observed when compared with the [8- + cells (compare Table 3 with Table  4 ). Again, the GCV metabolite levels increased in function of incubation time and were markedly higher (fiveto 10-fold) in FM3Atk − /HSV-1tk + than FM3A/0 cells. Interestingly, no traces of E-GCV-MP, E-GCV-DP and E-GCV-TP were observed. The radiolabeled anabolites exactly coeluted with the different GCV phosphate derivatives, previously found in GCV-treated cells. Only the radiolabeled fraction that eluted at the very beginning of the chromatography procedure (2-3 min) presumably reflects a mixture of E-GCV and GCV (Table 4) .
Since no major differences in metabolic properties of GCV and E-GCV were observed in FM3A cell cultures upon continuous exposure of the cells to both drugs, the retention of the intracellular [8- C]E-GCV for a 24-h period, upon which the drug was carefully removed from the extracellular medium after four subsequent washings of the cells (Figure 3 ). Whereas 50% of the initial intracellular E-GCV/GCV levels persisted for at least 2 to 26 h in E-GCV-treated FM3Atk − /HSV-1tk + cells, GCV levels decreased to 34% within 2 h after [8] [9] [10] [11] [12] [13] [14] C]E-GCV in nontransfected FM3A/0 and HSV-1tk genetransfected FM3A cells was essentially as described in the footnote to Table 3 . ND, not detectable.
2-3 min 9-10 min 16-17 min 27-28 min (GCV/E-GCV) (GCV-MP) (GCV-DP) (GCV-TP)
careful wash-out of the extracellular drug and then further decayed during the following 68 h (Figure 3a) . At 7 h after removal of the drug, the intracellular levels of GCV-TP derived from GCV had decreased by approximately 10-20%, whereas those derived from E-GCV were rather increased (Figure 3b) . However, at 20 to 68 h after removal of the radiolabeled drugs, the intracellular GCV-TP levels started to decrease to a markedly higher extent in GCV-treated cell cultures than in E-GCV-treated cell cultures, resulting in the retention of less than 10% GCV-TP levels in GCV-treated FM3Atk − /HSV-1tk + cell cultures, but retention of approximately 35% GCV-TP levels in E-GCV-treated FM3Atk − /HSV-1tk + cells. Thus, the half-life of the intracellular retention of GCV-TP (approximately 50 h) was markedly longer in E-GCVtreated cells than GCV-treated cells (half-life of the intracellular retention, approximately 20 h). A similar trend was also observed for the intracellular retention of GCV-DP levels and to a lesser extent also for GCV-MP levels (data not shown). Figure 3c shows the decay of total amounts of phosphorylated GCV metabolites (ie GCV-MP, GCV-DP and GCV-TP) in function of incubation time after removal of the radiolabeled drugs from the culture medium. The data essentially show a similar picture as observed for GCV-TP. Thus, our studies revealed that the superior antiviral and cytostatic properties of E-GCV are due to a markedly longer intracellular retention of phosphorylated GCV metabolites.
Whilst GCV is a substrate for HSV-1tk (K m approximately 45 M), 22 E-GCV does not act as a substrate for the purified HSV-1tk (K i ӷ 200 M). The latter observation indicates that E-GCV is not inhibitory in its own right but must be obligatorily converted to its parent drug GCV before it can exert its antiherpetic or cytostatic activity. Therefore, E-GCV should be considered as a prodrug of GCV that acts as an extracellular and intracellular depot form of GCV. This is in full agreement with our findings that no phosphorylated metabolites of E-GCV could be detected in HSVtk gene-transfected cells. The marked intracellular retention of parent E-GCV in E-GCV-treated tumor cells most likely results in a continuous intracellular release of GCV that then, in turn, can be converted to its phosphorylated metabolites by the herpetic tk and subsequently, by cellular nucleotide kinases.
Stability studies with E-GCV revealed that E-GCV is not spontaneously or enzymatically converted to a marked extent by enzymes that are present in the serum of the cell culture medium (fetal calf serum), as well as human serum within 6 h of incubation at 37°C. In fact, incubation of E-GCV in fetal calf serum and in human serum at 37°C revealed that approximately 50% of the initial intact E-GCV derivative could still be recovered after 24 h of incubation (data not shown). Therefore, we assume that conversion of E-GCV to GCV must occur intracellularly by cellular esterases. Although the nature of the esterases responsible for the cleavage of E-GCV to GCV is not known, it is assumed that the action of a variety of esterases or other cellular enzyme activities may result in the release of GCV from E-GCV. Therefore, resistance of tumor cells against the cytostatic activity of E-GCV is unlikely to occur rapidly as a result of the selection of mutated enzymes. Moreover, whereas inhibitors of nucleoside uptake (ie NBMPR and pyridamole) partially reverse the cytostatic activity of GCV against HSVtk gene-transfected tumor cells, they did not affect the antiproliferative activity of E-GCV (data not shown). These observations suggest that potential resistance development at the level of drug uptake is unlikely to occur with E-GCV, but may emerge in the presence of GCV.
The potential bystander effect of both GCV and E-GCV against HSVtk gene-transfected FM3A cells could not be investigated since the FM3Atk − /HSVtk + cells are growing in suspension. Therefore, we performed an experiment with HSV-1tk gene-transfected human osteosarcoma cells (OST). When these cells were mixed with the parental nontransfected OST cells at 90:10, 50:50, 10:90 and 4:96 ratios, both GCV and E-GCV completely killed the cell cultures at 5 M within 3 days. Control cultures that contained the same ratios of HSV-1tk gene-transfected and nontransfected OST cells kept their viability in the absence of GCV and E-GCV. These results point to a marked bystander effect of both GCV and E-GCV. However, we could not find a difference in the potential of E-GCV versus GCV to afford their bystander effect.
Since ganciclovir is currently envisaged for the selective treatment of tumors transfected with the HSV-1tk gene (including gliomas in the brain), we believe that E-GCV may be an interesting candidate compound for further studies in combined gene/chemotherapy trials of HSVtk gene-transfected tumors. Indeed, due to its much higher lipophilic properties (partition coefficient Pa in octanol:water for E-GCV: у10; and for GCV: Ͻ0.1), it may be expected that E-GCV -due to its apparent extracellular stability in human serum -may more efficiently cross the blood-brain barrier which may result in higher GCV levels in the brain tumor cells than if the parental drug GCV is administered. In addition, significantly higher antitumor activity against HSVtk gene-transfected tumors may be expected for E-GCV than for GCV.
The marked increase in antiviral and cytostatic properties noted following elaidic acid ester derivatization of ganciclovir suggests that a similar approach may be worth investigating for the recently reported pyrimidine nucleoside analogues that are endowed with a potent and selective cytostatic activity against HSVtk gene-transfected tumor cell lines. 10, [22] [23] [24] [25] In conclusion, E-GCV proved superior to GCV both in terms of antiherpetic activity and cytostatic activity against tumor cells transfected with the tk genes of HSV-1 or HSV-2. We demonstrated that the elaidic acid ester of GCV afforded a substantially longer retention of phosphorylated GCV derivatives than its parent drug GCV in HSVtk gene-transfected tumor cells. The elaidic acid ester derivative of GCV should be considered as a novel approach to potentiate the biological properties of GCV in HSVtk gene-transfected tumor cells. Moreover, these investigations should be extended to elaidic acid ester derivatives of other nucleoside analogues with antiviral and/or anticancer potential. 
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Figure 3 Decay of intracellular GCV and E-GCV (a), GCV-TP (b) and GCV-MP + GCV-DP + GCV-TP (c) levels in FM3Atk
